X @Bloomberg

Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split. https://t.co/mULsEpYYXs ...